{
    "abstract": "Streptococcus agalactiae (group B streptococcus (GBS)) is the leading cause of neonatal sepsis and meningitis in many countries. Intrapartum antibiotic strategies have reduced the incidence of early-onset neonatal GBS in a number of countries but have had no impact on late onset GBS infection (LOD). In low/middle income settings, the disease burden remains uncertain although in several countries of Southern Africa appears comparable to or higher than that of high-income countries. As disease may be rapidly fulminating cases can be missed before appropriate samples are obtained and this may lead to underestimation of the true burden. Given the rapid onset and progression within hours of birth as well as the deficiencies in IAP strategies and absence of a solution for preventing LOD, it is clear that administration of a suitable vaccine in pregnancy could provide a better solution in all settings; it should also be cost effective. The current leading vaccine candidates are CPS-protein conjugate vaccines but protein-based vaccines are also in development and one has recently commenced clinical trials.",
    "author_highlights": [
        {
            "endOffset": 5173,
            "sentence": "Group B streptococcus is the leading cause of neonatal sepsis and meningitis in many countries.",
            "startOffset": 5078
        },
        {
            "endOffset": 5271,
            "sentence": "Intrapartum antibiotics have no impact on late onset infections and minimal impact on meningitis.",
            "startOffset": 5174
        },
        {
            "endOffset": 5364,
            "sentence": "A suitable vaccine, given in pregnancy, could provide an effective solution in all settings.",
            "startOffset": 5272
        },
        {
            "endOffset": 5451,
            "sentence": "The leading vaccine candidates are capsular polysaccharide-protein conjugate vaccines.",
            "startOffset": 5365
        },
        {
            "endOffset": 5542,
            "sentence": "Licensure may require efficacy trials or be based on serological correlates of protection.",
            "startOffset": 5452
        }
    ],
    "bib_entries": {
        "bib0195": {
            "authors": [
                {
                    "first": "Stephanie J.",
                    "initial": "S.J.",
                    "last": "Schrag"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Zywicki"
                },
                {
                    "first": "Monica M.",
                    "initial": "M.M.",
                    "last": "Farley"
                },
                {
                    "first": "Arthur L.",
                    "initial": "A.L.",
                    "last": "Reingold"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Lewis B.",
                    "initial": "L.B.",
                    "last": "Lefkowitz"
                },
                {
                    "first": "James L.",
                    "initial": "J.L.",
                    "last": "Hadler"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Danila"
                },
                {
                    "first": "Paul R.",
                    "initial": "P.R.",
                    "last": "Cieslak"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuchat"
                }
            ],
            "doi": "10.1056/NEJM200001063420103",
            "firstpage": "15",
            "issn": "00284793",
            "lastpage": "20",
            "pmid": "10620644",
            "pub_year": 2000,
            "title": "Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis",
            "volume": "342"
        },
        "bib0200": {
            "authors": [
                {
                    "first": "Katherine J.",
                    "initial": "K.J.",
                    "last": "Gray"
                },
                {
                    "first": "Sally L.",
                    "initial": "S.L.",
                    "last": "Bennett"
                },
                {
                    "first": "Neil",
                    "initial": "N.",
                    "last": "French"
                },
                {
                    "first": "Amos J.",
                    "initial": "A.J.",
                    "last": "Phiri"
                },
                {
                    "first": "Stephen M.",
                    "initial": "S.M.",
                    "last": "Graham"
                }
            ],
            "doi": "10.3201/eid1302.060680",
            "firstpage": "223",
            "issn": "10806040",
            "lastpage": "229",
            "pmid": "17479883",
            "pub_year": 2007,
            "title": "Invasive group B streptococcal infection in infants, Malawi",
            "volume": "13"
        },
        "bib0205": {
            "authors": [
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Kholeka",
                    "initial": "K.",
                    "last": "Radebe"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Crewe-Brown"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Guthrie",
                    "initial": "G.",
                    "last": "Arakere"
                },
                {
                    "first": "Mantoa",
                    "initial": "M.",
                    "last": "Mokhachane"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Kimura"
                }
            ],
            "doi": "10.1179/000349803125002814",
            "firstpage": "15",
            "issn": "02724936",
            "lastpage": "23",
            "pmid": "12648320",
            "pub_year": 2003,
            "title": "High burden of invasive Streptococcus agalactiae disease in South African infants",
            "volume": "23"
        },
        "bib0210": {
            "authors": [
                {
                    "first": "Alemnew F.",
                    "initial": "A.F.",
                    "last": "Dagnew"
                },
                {
                    "first": "Marianne C.",
                    "initial": "M.C.",
                    "last": "Cunnington"
                },
                {
                    "first": "Queen",
                    "initial": "Q.",
                    "last": "Dube"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Neil",
                    "initial": "N.",
                    "last": "French"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Heyderman"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Slobod"
                },
                {
                    "first": "Sue Ann Costa",
                    "initial": "S.A.C.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1093/cid/cis395",
            "firstpage": "91",
            "issn": "10584838",
            "lastpage": "102",
            "pmid": "22523262",
            "pub_year": 2012,
            "title": "Variation in reported neonatal group B streptococcal disease incidence in developing countries",
            "volume": "55"
        },
        "bib0215": {
            "authors": [
                {
                    "first": "Karen M.",
                    "initial": "K.M.",
                    "last": "Edmond"
                },
                {
                    "first": "Christina",
                    "initial": "C.",
                    "last": "Kortsalioudaki"
                },
                {
                    "first": "Susana",
                    "initial": "S.",
                    "last": "Scott"
                },
                {
                    "first": "Stephanie J.",
                    "initial": "S.J.",
                    "last": "Schrag"
                },
                {
                    "first": "Anita Km",
                    "initial": "A.K.",
                    "last": "Zaidi"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Cousens"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                }
            ],
            "doi": "10.1016/S0140-6736(11)61651-6",
            "firstpage": "547",
            "issn": "01406736",
            "lastpage": "556",
            "pmid": "22226047",
            "pub_year": 2012,
            "title": "Group B streptococcal disease in infants aged younger than 3 months: Systematic review and meta-analysis",
            "volume": "379"
        },
        "bib0220": {
            "authors": [
                {
                    "first": "Nicola",
                    "initial": "N.",
                    "last": "Jones"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Oliver"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Jones"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Haines"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Crook"
                }
            ],
            "doi": "10.1136/jcp.2005.029058",
            "firstpage": "363",
            "issn": "00219746",
            "lastpage": "366",
            "pmid": "16473927",
            "pub_year": 2006,
            "title": "Carriage of group B streptococcus in pregnant women from Oxford, UK",
            "volume": "59"
        },
        "bib0225": {
            "authors": [
                {
                    "first": "Michel G.",
                    "initial": "M.G.",
                    "last": "Bergeron"
                },
                {
                    "first": "Danbing",
                    "initial": "D.",
                    "last": "Ke"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Menard"
                },
                {
                    "first": "Fran\u00e7ois J.",
                    "initial": "F.J.",
                    "last": "Picard"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Gagnon"
                },
                {
                    "first": "Marthe",
                    "initial": "M.",
                    "last": "Bernier"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Ouellette"
                },
                {
                    "first": "Paul H.",
                    "initial": "P.H.",
                    "last": "Roy"
                },
                {
                    "first": "Sylvie",
                    "initial": "S.",
                    "last": "Marcoux"
                },
                {
                    "first": "William D.",
                    "initial": "W.D.",
                    "last": "Fraser"
                }
            ],
            "doi": "10.1056/NEJM200007203430303",
            "firstpage": "175",
            "issn": "00284793",
            "lastpage": "179",
            "pmid": "10900276",
            "pub_year": 2000,
            "title": "Rapid detection of group B streptococci in pregnant women at delivery",
            "volume": "343"
        },
        "bib0230": {
            "authors": [
                {
                    "first": "P. T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "G. F.",
                    "initial": "G.F.",
                    "last": "Balfour"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Tighe"
                },
                {
                    "first": "N. Q.",
                    "initial": "N.Q.",
                    "last": "Verlander"
                },
                {
                    "first": "T. L.",
                    "initial": "T.L.",
                    "last": "Lamagni"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Efstratiou"
                }
            ],
            "doi": "10.1136/adc.2008.148874",
            "firstpage": "674",
            "issn": "00039888",
            "lastpage": "680",
            "pmid": "19457879",
            "pub_year": 2009,
            "title": "Group B streptococcal disease in infants: A case control study",
            "volume": "94"
        },
        "bib0235": {
            "authors": [],
            "firstpage": "1",
            "issn": "10575987",
            "lastpage": "24",
            "pmid": "8637497",
            "pub_year": 1996,
            "title": "Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention.",
            "volume": "45"
        },
        "bib0240": {
            "authors": [
                {
                    "first": "Romina",
                    "initial": "R.",
                    "last": "Libster"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Fatma",
                    "initial": "F.",
                    "last": "Levent"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Luis A.",
                    "initial": "L.A.",
                    "last": "Castagnini"
                },
                {
                    "first": "Timothy",
                    "initial": "T.",
                    "last": "Cooper"
                },
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Sparks"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Prachi E.",
                    "initial": "P.E.",
                    "last": "Shah"
                }
            ],
            "doi": "10.1542/peds.2011-3453",
            "firstpage": "e8",
            "issn": "00314005",
            "lastpage": "e15",
            "pmid": "22689869",
            "pub_year": 2012,
            "title": "Long-term outcomes of group B streptococcal meningitis",
            "volume": "130"
        },
        "bib0245": {
            "authors": [
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Bedford"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "de Louvois"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Halket"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Peckham"
                },
                {
                    "first": "Rosalinde",
                    "initial": "R.",
                    "last": "Hurley"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Harvey"
                }
            ],
            "doi": "10.1136/bmj.323.7312.533",
            "firstpage": "533",
            "issn": "09598138",
            "pmid": "11546697",
            "pub_year": 2001,
            "title": "Meningitis in infancy in England and Wales: Follow up at age 5 years",
            "volume": "323"
        },
        "bib0250": {
            "authors": [
                {
                    "first": "Sun Young",
                    "initial": "S.Y.",
                    "last": "Kim"
                },
                {
                    "first": "Louise B.",
                    "initial": "L.B.",
                    "last": "Russell"
                },
                {
                    "first": "Jeehyun",
                    "initial": "J.",
                    "last": "Park"
                },
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Verani"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Clare L.",
                    "initial": "C.L.",
                    "last": "Cutland"
                },
                {
                    "first": "Stephanie J.",
                    "initial": "S.J.",
                    "last": "Schrag"
                },
                {
                    "first": "Anushua",
                    "initial": "A.",
                    "last": "Sinha"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.01.062",
            "firstpage": "1954",
            "issn": "0264410X",
            "lastpage": "1963",
            "pmid": "24530145",
            "pub_year": 2014,
            "title": "Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa",
            "volume": "32"
        },
        "bib0255": {
            "authors": [
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Nan"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Dangor"
                },
                {
                    "first": "C. L.",
                    "initial": "C.L.",
                    "last": "Cutland"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "M. C.",
                    "initial": "M.C.",
                    "last": "Cunnington"
                }
            ],
            "doi": "10.1111/1471-0528.13527",
            "firstpage": "1437",
            "issn": "14700328",
            "lastpage": "1445",
            "pmid": "26177561",
            "pub_year": 2015,
            "title": "Maternal group B Streptococcus-related stillbirth: A systematic review",
            "volume": "122"
        },
        "bib0260": {
            "authors": [
                {
                    "first": "Rebecca C.",
                    "initial": "R.C.",
                    "last": "Lancefield"
                }
            ],
            "doi": "10.1084/jem.67.1.25",
            "firstpage": "25",
            "issn": "00221007",
            "lastpage": "40",
            "pub_year": 1938,
            "title": "Two serological types of group b hemolytic streptococci with related, but not identical, type-specific substances",
            "volume": "67"
        },
        "bib0265": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Carpenter"
                },
                {
                    "first": "Bethany M.",
                    "initial": "B.M.",
                    "last": "Hays"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "doi": "10.1056/NEJM198811033191802",
            "firstpage": "1180",
            "issn": "00284793",
            "lastpage": "1185",
            "pmid": "3050524",
            "pub_year": 1988,
            "title": "Immunization of Pregnant Women with a Polysaccharide Vaccine of Group B Streptococcus",
            "volume": "319"
        },
        "bib0270": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Marisol",
                    "initial": "M.",
                    "last": "Fernandez"
                },
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Paoletti"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                }
            ],
            "doi": "10.1086/375536",
            "firstpage": "66",
            "issn": "00221899",
            "lastpage": "73",
            "pmid": "12825173",
            "pub_year": 2003,
            "title": "Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III",
            "volume": "188"
        },
        "bib0275": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Pamela",
                    "initial": "P.",
                    "last": "McInnes"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00353-0",
            "firstpage": "3468",
            "issn": "0264410X",
            "lastpage": "3472",
            "pmid": "12850362",
            "pub_year": 2003,
            "title": "Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine",
            "volume": "21"
        },
        "bib0280": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Paoletti"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Wessels"
                },
                {
                    "first": "Hilde Kari",
                    "initial": "H.K.",
                    "last": "Guttormsen"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Melissa E.",
                    "initial": "M.E.",
                    "last": "Hickman"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "doi": "10.1086/314574",
            "firstpage": "142",
            "issn": "00221899",
            "lastpage": "150",
            "pmid": "9841833",
            "pub_year": 1999,
            "title": "Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib",
            "volume": "179"
        },
        "bib0285": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Paoletti"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Hilde Kari",
                    "initial": "H.K.",
                    "last": "Guttormsen"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "doi": "10.1086/382193",
            "firstpage": "1103",
            "issn": "00221899",
            "lastpage": "1112",
            "pmid": "14999615",
            "pub_year": 2004,
            "title": "Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines",
            "volume": "189"
        },
        "bib0290": {
            "authors": [],
            "firstpage": "461",
            "issn": "00498114",
            "lastpage": "476",
            "pmid": "23210147",
            "pub_year": 2012,
            "title": "Vaccines against influenza WHO position paper - November 2012.",
            "volume": "87"
        },
        "bib0295": {
            "authors": [
                {
                    "first": "Gayatri",
                    "initial": "G.",
                    "last": "Amirthalingam"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Edna",
                    "initial": "E.",
                    "last": "Kara"
                },
                {
                    "first": "Katherine",
                    "initial": "K.",
                    "last": "Donegan"
                },
                {
                    "first": "Norman K.",
                    "initial": "N.K.",
                    "last": "Fry"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                }
            ],
            "doi": "10.1016/S0140-6736(14)60686-3",
            "firstpage": "1521",
            "issn": "01406736",
            "lastpage": "1528",
            "pmid": "25037990",
            "pub_year": 2014,
            "title": "Effectiveness of maternal pertussis vaccination in England: An observational study",
            "volume": "384"
        },
        "bib0300": {
            "authors": [
                {
                    "first": "Stephanie J.",
                    "initial": "S.J.",
                    "last": "Schrag"
                },
                {
                    "first": "Elizabeth R.",
                    "initial": "E.R.",
                    "last": "Zell"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Lynfield"
                },
                {
                    "first": "Aaron",
                    "initial": "A.",
                    "last": "Roome"
                },
                {
                    "first": "Kathryn E.",
                    "initial": "K.E.",
                    "last": "Arnold"
                },
                {
                    "first": "Allen S.",
                    "initial": "A.S.",
                    "last": "Craig"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Arthur",
                    "initial": "A.",
                    "last": "Reingold"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Stefonek"
                },
                {
                    "first": "Glenda",
                    "initial": "G.",
                    "last": "Smith"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Gamble"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuchat"
                }
            ],
            "doi": "10.1056/NEJMoa020205",
            "firstpage": "233",
            "issn": "00284793",
            "lastpage": "239",
            "pmid": "12140298",
            "pub_year": 2002,
            "title": "A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates",
            "volume": "347"
        },
        "bib0305": {
            "authors": [
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Salisbury"
                }
            ],
            "firstpage": "34",
            "issn": "10344810",
            "lastpage": "36",
            "pmid": "11885735",
            "pub_year": 2001,
            "title": "Introduction of a conjugate meningococcal type C vaccine programme in the UK",
            "volume": "37"
        },
        "bib0310": {
            "authors": [
                {
                    "first": "Jeffrey N.",
                    "initial": "J.N.",
                    "last": "Roberts"
                },
                {
                    "first": "Marion F.",
                    "initial": "M.F.",
                    "last": "Gruber"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.12.068",
            "firstpage": "966",
            "issn": "0264410X",
            "lastpage": "972",
            "pmid": "25573034",
            "pub_year": 2015,
            "title": "Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy",
            "volume": "33"
        },
        "bib0315": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "doi": "10.1056/NEJM197604012941404",
            "firstpage": "753",
            "issn": "00284793",
            "lastpage": "756",
            "pmid": "768760",
            "pub_year": 1976,
            "title": "Correlation of Maternal Antibody Deficiency with Susceptibility to Neonatal Group B Streptococcal Infection",
            "volume": "294"
        },
        "bib0320": {
            "authors": [
                {
                    "first": "Ziyaad",
                    "initial": "Z.",
                    "last": "Dangor"
                },
                {
                    "first": "Gaurav",
                    "initial": "G.",
                    "last": "Kwatra"
                },
                {
                    "first": "Alane",
                    "initial": "A.",
                    "last": "Izu"
                },
                {
                    "first": "Sanjay G.",
                    "initial": "S.G.",
                    "last": "Lala"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                }
            ],
            "doi": "10.1586/14760584.2014.953939",
            "firstpage": "135",
            "issn": "14760584",
            "lastpage": "149",
            "pmid": "25242617",
            "pub_year": 2014,
            "title": "Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants",
            "volume": "14"
        },
        "bib0325": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Vincent J.",
                    "initial": "V.J.",
                    "last": "Carey"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Sharon L.",
                    "initial": "S.L.",
                    "last": "Hillier"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Platt"
                }
            ],
            "doi": "10.1093/infdis/jit549",
            "firstpage": "781",
            "issn": "00221899",
            "lastpage": "788",
            "pmid": "24133184",
            "pub_year": 2014,
            "title": "Maternal antibody at delivery protects neonates from early onset group B streptococcal disease",
            "volume": "209"
        },
        "bib0330": {
            "authors": [
                {
                    "first": "Feng Ying C.",
                    "initial": "F.Y.C.",
                    "last": "Lin"
                },
                {
                    "first": "Leonard E.",
                    "initial": "L.E.",
                    "last": "Weisman"
                },
                {
                    "first": "Parvin H.",
                    "initial": "P.H.",
                    "last": "Azimi"
                },
                {
                    "first": "Joseph B.",
                    "initial": "J.B.",
                    "last": "Philips"
                },
                {
                    "first": "Penny",
                    "initial": "P.",
                    "last": "Clark"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Regan"
                },
                {
                    "first": "George G.",
                    "initial": "G.G.",
                    "last": "Rhoads"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Barry M.",
                    "initial": "B.M.",
                    "last": "Gray"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Troendle"
                },
                {
                    "first": "Ruth A.",
                    "initial": "R.A.",
                    "last": "Brenner"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Moyer"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1086/422756",
            "firstpage": "928",
            "issn": "00221899",
            "lastpage": "934",
            "pmid": "15295698",
            "pub_year": 2004,
            "title": "Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen",
            "volume": "190"
        },
        "bib0335": {
            "authors": [
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Wessels"
                },
                {
                    "first": "Hilde Kari",
                    "initial": "H.K.",
                    "last": "Guttormsen"
                },
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Paoletti"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                }
            ],
            "firstpage": "4303",
            "issn": "00199567",
            "lastpage": "4305",
            "pmid": "10447392",
            "pub_year": 1999,
            "title": "Measurement of human antibodies to type III group B Streptococcus (multiple letters)",
            "volume": "67"
        },
        "bib0340": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Kwatra"
                },
                {
                    "first": "P. V.",
                    "initial": "P.V.",
                    "last": "Adrian"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Shiri"
                },
                {
                    "first": "E. J.",
                    "initial": "E.J.",
                    "last": "Buchmann"
                },
                {
                    "first": "C. L.",
                    "initial": "C.L.",
                    "last": "Cutland"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                }
            ],
            "doi": "10.1016/j.cmi.2015.01.030",
            "firstpage": "568",
            "issn": "1198743X",
            "lastpage": "568.e21",
            "pmid": "25680313",
            "pub_year": 2015,
            "title": "Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women",
            "volume": "21"
        },
        "bib0345": {
            "authors": [
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Ziyaad",
                    "initial": "Z.",
                    "last": "Dangor"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Schrag"
                },
                {
                    "first": "Alaine",
                    "initial": "A.",
                    "last": "Izu"
                },
                {
                    "first": "Ajoke",
                    "initial": "A.",
                    "last": "Sobanjo-ter Meulen"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.02.029",
            "firstpage": "D52",
            "issn": "0264410X",
            "lastpage": "D57",
            "pmid": "23973347",
            "pub_year": 2013,
            "title": "Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants",
            "volume": "31"
        },
        "bib0350": {
            "authors": [
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                }
            ],
            "doi": "10.1586/erv.11.61",
            "firstpage": "685",
            "issn": "14760584",
            "lastpage": "694",
            "pmid": "21604988",
            "pub_year": 2011,
            "title": "An update on vaccination against group B streptococcus",
            "volume": "10"
        },
        "bib0355": {
            "authors": [
                {
                    "first": "L. C.",
                    "initial": "L.C.",
                    "last": "Paoletti"
                },
                {
                    "first": "M. A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "D. L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Molrine"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Ambrosino"
                },
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Baker"
                }
            ],
            "doi": "10.1128/IAI.69.11.6696-6701.2001",
            "firstpage": "6696",
            "issn": "00199567",
            "lastpage": "6701",
            "pmid": "11598040",
            "pub_year": 2001,
            "title": "Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines",
            "volume": "69"
        },
        "bib0360": {
            "authors": [
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Heidi J.",
                    "initial": "H.J.",
                    "last": "Lane"
                },
                {
                    "first": "Sharon L.",
                    "initial": "S.L.",
                    "last": "Hillier"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.04.048",
            "firstpage": "4123",
            "issn": "0264410X",
            "lastpage": "4126",
            "pmid": "22537994",
            "pub_year": 2012,
            "title": "Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines",
            "volume": "30"
        },
        "bib0365": {
            "authors": [
                {
                    "first": "Charlotte",
                    "initial": "C.",
                    "last": "Larsson"
                },
                {
                    "first": "Margaretha",
                    "initial": "M.",
                    "last": "St\u00e5lhammar-Carlemalm"
                },
                {
                    "first": "Gunnar",
                    "initial": "G.",
                    "last": "Lindahl"
                }
            ],
            "doi": "10.1016/S0264-410X(98)00218-7",
            "firstpage": "454",
            "issn": "0264410X",
            "lastpage": "458",
            "pmid": "10073723",
            "pub_year": 1999,
            "title": "Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine",
            "volume": "17"
        },
        "bib0370": {
            "authors": [
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Larsson"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Lindroth"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Nordin"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "St\u00e5lhammar-Carlemalm"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Lindahl"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Krantz"
                }
            ],
            "doi": "10.1136/adc.2005.090472",
            "firstpage": "F403",
            "issn": "13592998",
            "lastpage": "F408",
            "pmid": "17056838",
            "pub_year": 2006,
            "title": "Association between low concentrations of antibodies to protein \u03b1 and Rib and invasive neonatal group B streptococcal infection",
            "volume": "91"
        },
        "bib0375": {
            "authors": [
                {
                    "first": "Immaculada",
                    "initial": "I.",
                    "last": "Margarit"
                },
                {
                    "first": "Cira Daniela",
                    "initial": "C.D.",
                    "last": "Rinaudo"
                },
                {
                    "first": "Cesira L.",
                    "initial": "C.L.",
                    "last": "Galeotti"
                },
                {
                    "first": "Domenico",
                    "initial": "D.",
                    "last": "Maione"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Ghezzo"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Buttazzoni"
                },
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Rosini"
                },
                {
                    "first": "Ylenia",
                    "initial": "Y.",
                    "last": "Runci"
                },
                {
                    "first": "Marirosa",
                    "initial": "M.",
                    "last": "Mora"
                },
                {
                    "first": "Scilla",
                    "initial": "S.",
                    "last": "Buccato"
                },
                {
                    "first": "Massimiliano",
                    "initial": "M.",
                    "last": "Pagani"
                },
                {
                    "first": "Eleonora",
                    "initial": "E.",
                    "last": "Tresoldi"
                },
                {
                    "first": "Alberto",
                    "initial": "A.",
                    "last": "Berardi"
                },
                {
                    "first": "Roberta",
                    "initial": "R.",
                    "last": "Creti"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "John L.",
                    "initial": "J.L.",
                    "last": "Telford"
                },
                {
                    "first": "Guido",
                    "initial": "G.",
                    "last": "Grandi"
                }
            ],
            "doi": "10.1086/595564",
            "firstpage": "108",
            "issn": "00221899",
            "lastpage": "115",
            "pmid": "19086816",
            "pub_year": 2009,
            "title": "Preventing bacterial infections with pilus-based vaccines: The group B streptococcus paradigm",
            "volume": "199"
        },
        "bib0380": {
            "authors": [
                {
                    "first": "Gerry",
                    "initial": "G.",
                    "last": "Oster"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Edelsberg"
                },
                {
                    "first": "Kalin",
                    "initial": "K.",
                    "last": "Hennegan"
                },
                {
                    "first": "Clement",
                    "initial": "C.",
                    "last": "Lewin"
                },
                {
                    "first": "Vas",
                    "initial": "V.",
                    "last": "Narasimhan"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Slobod"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.06.003",
            "firstpage": "4778",
            "issn": "0264410X",
            "lastpage": "4785",
            "pmid": "24992717",
            "pub_year": 2014,
            "title": "Prevention of group B streptococcal disease in the first 3 months of life: Would routine maternal immunization during pregnancy be cost-effective?",
            "volume": "32"
        }
    },
    "body_text": [
        {
            "endOffset": 8878,
            "parents": [],
            "refoffsets": {
                "bib0230": {
                    "endOffset": 8877,
                    "startOffset": 8874
                }
            },
            "secId": "sec0005",
            "sentence": "Disease may occur rapidly; signs are evident at birth or within 12 h in over 90% of cases and presentation is typically with pneumonia or sepsis [8].",
            "startOffset": 8729,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 7616,
            "parents": [],
            "refoffsets": {
                "bib0200": {
                    "endOffset": 7615,
                    "startOffset": 7610
                },
                "bib0205": {
                    "endOffset": 7615,
                    "startOffset": 7610
                }
            },
            "secId": "sec0005",
            "sentence": "In low and middle-income country (LMIC) settings, the disease burden remains uncertain although in several countries of Southern Africa appears comparable to or higher than that of high-income countries (HIC) [2,3].",
            "startOffset": 7401,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 20308,
            "parents": [],
            "secId": "sec0030",
            "sentence": "In the 1970s and 1980s human trials with plain capsular polysaccharide vaccines, including in pregnant women (STIII), demonstrated them to be well tolerated but modestly immunogenic.",
            "startOffset": 20126,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 22020,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The GBS conjugate vaccine was well tolerated, GBS III-specific IgG rose from 0.18 \u03bcg/ml before vaccination to 9.76 \u03bcg/ml at delivery, showed excellent transplacental transfer of antibody (cord/maternal ratio: 0.8) and elevated concentrations of antibody persisted in the infants up to 2 months of age.",
            "startOffset": 21719,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 12211,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "CPS remains the best-studied target of GBS, and until recently was the only target for which human vaccine trials have been undertaken.",
            "startOffset": 12076,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 24806,
            "parents": [],
            "refoffsets": {
                "bib0380": {
                    "endOffset": 24805,
                    "startOffset": 24801
                }
            },
            "secId": "sec0035",
            "sentence": "In the US-based study, the cost/QALY ($91,321) for a trivalent GBS vaccine was found to be comparable to other ACIP-recommended vaccines [38].",
            "startOffset": 24664,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 19874,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Impact (and timing of the impact) of vaccine on GBS colonization (including density and the impact on non-vaccine ST) at delivery, on vertical transmission, on infant colonization and on persistence of antibody duration.",
            "startOffset": 19654,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 25153,
            "parents": [],
            "secId": "sec0035",
            "sentence": "These studies, in addition to more comprehensive data on the burden of disease in LMICs will likely increase awareness of the potential for vaccine impact, and in turn, increase the likelihood for financing.",
            "startOffset": 24946,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 14851,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0020",
            "sentence": "Pre-pregnancy or adolescent vaccination may also be considered, but are less feasible, especially in LMIC settings where there is no current platform for vaccination in these groups.",
            "startOffset": 14669,
            "title": "General approaches to vaccine development for this disease for low and middle income country"
        },
        {
            "endOffset": 10863,
            "parents": [],
            "secId": "sec0005",
            "sentence": "A recently published decision-analytic model based on South African data compared four strategies: no intervention, maternal GBS vaccination, RFB-IAP, and vaccination plus RFB-IAP.",
            "startOffset": 10683,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 21615,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Only one pregnancy trial with a III tetanus toxoid conjugate has been published.",
            "startOffset": 21535,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 11505,
            "parents": [],
            "refoffsets": {
                "bib0250": {
                    "endOffset": 11494,
                    "startOffset": 11490
                }
            },
            "secId": "sec0005",
            "sentence": "It was concluded that vaccination would substantially reduce the burden of infant GBS disease in South Africa and would be very cost-effective by WHO guidelines [12] (Table 1).",
            "startOffset": 11329,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 19958,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Impact on colonization could also serve as a surrogate endpoint for vaccine trials.",
            "startOffset": 19875,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 16267,
            "parents": [],
            "secId": "sec0025",
            "sentence": "This is a new paradigm for regulators as currently no vaccine is licensed specifically for this use.",
            "startOffset": 16167,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 20412,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Better immunogenicity was then shown with conjugate vaccines.",
            "startOffset": 20351,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 19427,
            "parents": [],
            "secId": "sec0025",
            "sentence": "These studies could contribute to the licensure pathway of a GBS vaccine without needing to undertake large-scale efficacy trials in pregnant women.",
            "startOffset": 19279,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 7105,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The highest incidence of all is in the first 3 months of life and this review will focus on this group.",
            "startOffset": 7002,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 12844,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "Essentially all of these clinical vaccine studies were coordinated by a key group of investigators in the USA with funding and sponsorship through the National Institutes of Health and National Institute of Allergy and Infectious Diseases.",
            "startOffset": 12605,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 15243,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0300": {
                    "endOffset": 15180,
                    "startOffset": 15176
                }
            },
            "secId": "sec0020",
            "sentence": "Additionally, evidence from cohort studies suggests that IAP based on swab-based screening at 35\u201337 weeks is a superior strategy to that based on risk factors [22]; however swab-based screening is significantly more expensive.",
            "startOffset": 15017,
            "title": "General approaches to vaccine development for this disease for low and middle income country"
        },
        {
            "endOffset": 22358,
            "parents": [],
            "refoffsets": {
                "bib0275": {
                    "endOffset": 22357,
                    "startOffset": 22353
                }
            },
            "secId": "sec0030",
            "sentence": "Efficient transplacental transfer of tetanus IgG was also reported, raising the possibility that such conjugates may also offer protection against neonatal tetanus [17].",
            "startOffset": 22189,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 23614,
            "parents": [],
            "secId": "sec0030",
            "sentence": "These proteins appear to have a broad distribution among GBS isolates.",
            "startOffset": 23544,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 7931,
            "parents": [],
            "refoffsets": {
                "bib0210": {
                    "endOffset": 7930,
                    "startOffset": 7927
                }
            },
            "secId": "sec0005",
            "sentence": "This may lead to significant underestimation of the true burden and be a particular issue in many African and Asian countries; comprehensive epidemiological data from such countries are urgently required [4].",
            "startOffset": 7723,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 10132,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Of particular importance is that IAP does not decrease LOD.",
            "startOffset": 10073,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 25459,
            "parents": [],
            "secId": "sec0040",
            "sentence": "He has been a consultant to Novartis and Pfizer on group B streptococcus vaccines but receives no funding for this.",
            "startOffset": 25344,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 24042,
            "parents": [],
            "refoffsets": {
                "bib0375": {
                    "endOffset": 24041,
                    "startOffset": 24037
                }
            },
            "secId": "sec0030",
            "sentence": "These protective antigens included proteins subsequently found to constitute pilus-like structures and capable of eliciting high titres of opsonophagocytic antibodies that protect mice in both active and passive immunization models [37].",
            "startOffset": 23805,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 8204,
            "parents": [],
            "refoffsets": {
                "bib0215": {
                    "endOffset": 8203,
                    "startOffset": 8200
                }
            },
            "secId": "sec0005",
            "sentence": "In African infants the incidence was 1.21 per 1000 live births, with a case fatality of 22% [5].",
            "startOffset": 8108,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 14668,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0020",
            "sentence": "Therefore, the obvious target for vaccination is pregnant women.",
            "startOffset": 14604,
            "title": "General approaches to vaccine development for this disease for low and middle income country"
        },
        {
            "endOffset": 20966,
            "parents": [],
            "refoffsets": {
                "bib0350": {
                    "endOffset": 20964,
                    "startOffset": 20960
                }
            },
            "secId": "sec0030",
            "sentence": "Monovalent conjugate vaccines incorporating each of the five major capsular polysaccharides of GBS have now been evaluated in phase 1 and 2 trials and in one study a bivalent conjugate vaccine was assessed (reviewed in [32]).",
            "startOffset": 20741,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 24354,
            "parents": [],
            "secId": "sec0035",
            "sentence": "The relatively well-characterized incidence of GBS in high income countries provides the market incentive for development of a vaccine, and historically NIH, and now large pharmaceutical companies, have supported costly clinical studies.",
            "startOffset": 24117,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 12390,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0265": {
                    "endOffset": 12358,
                    "startOffset": 12354
                }
            },
            "secId": "sec0015",
            "sentence": "In the 1980s, human trials with plain capsular carbohydrate based vaccines demonstrated that they were well tolerated, including in pregnancy [15], but only modestly immunogenic.",
            "startOffset": 12212,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 23543,
            "parents": [],
            "refoffsets": {
                "bib0365": {
                    "endOffset": 23542,
                    "startOffset": 23535
                },
                "bib0370": {
                    "endOffset": 23542,
                    "startOffset": 23535
                }
            },
            "secId": "sec0030",
            "sentence": "MinervaX, a privately held Danish biotech company, has recently initiated a Phase I clinical trial with a protein-only vaccine based on a fusion of two immunogenic and protective protein domains from selected surface proteins of GBS (N-terminals of AlphaC and Rib) [35,36].",
            "startOffset": 23270,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 8352,
            "parents": [],
            "secId": "sec0005",
            "sentence": "There are 10 GBS serotypes and ST Ia, II, III and V are responsible for most EOD.",
            "startOffset": 8271,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 16996,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Serological correlates of protection.",
            "startOffset": 16959,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 18934,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Again, standardization of methods is needed in order to facilitate the evaluation and comparison of preclinical and early stage clinical candidates using such assays prior to their advancement to late stage clinical testing.",
            "startOffset": 18710,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 13258,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "More recently, a vaccine manufacturer (Novartis, now GSK) has developed and commenced clinical trials with a new CPS conjugate vaccine, based on CRM197 as the conjugate protein.",
            "startOffset": 13081,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 8728,
            "parents": [],
            "refoffsets": {
                "bib0220": {
                    "endOffset": 8611,
                    "startOffset": 8606
                },
                "bib0225": {
                    "endOffset": 8611,
                    "startOffset": 8606
                }
            },
            "secId": "sec0005",
            "sentence": "An estimated 20\u201330% of pregnant women are colonized with GBS (data derived mostly from HIC [6,7]) and approximately 50% of their babies become colonized and 1% of these babies progress to develop invasive disease.",
            "startOffset": 8515,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 12604,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0270": {
                    "endOffset": 12603,
                    "startOffset": 12596
                },
                "bib0275": {
                    "endOffset": 12603,
                    "startOffset": 12596
                },
                "bib0280": {
                    "endOffset": 12603,
                    "startOffset": 12596
                },
                "bib0285": {
                    "endOffset": 12603,
                    "startOffset": 12596
                }
            },
            "secId": "sec0015",
            "sentence": "GBS polysaccharide-protein conjugate vaccines (predominantly using tetanus toxoid as the conjugate protein) were then developed and have subsequently been administered to healthy adults and pregnant women [16\u201319].",
            "startOffset": 12391,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 15775,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Multiple clinical studies have already been completed in order to assess the optimal dosage, schedule, requirement for adjuvant, and the persistence of response, as well as immunogenicity and safety trials in pregnant women.",
            "startOffset": 15551,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 19278,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Because IgG capsular antibodies are unlikely to be the only determinant of protection, measures of functional antibody are also required.",
            "startOffset": 19141,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 17739,
            "parents": [],
            "refoffsets": {
                "bib0320": {
                    "endOffset": 17738,
                    "startOffset": 17734
                }
            },
            "secId": "sec0025",
            "sentence": "For example, in a meta-analysis, the odds of invasive GBS disease were 6.56 (95% CI: 2.10\u201320.55) and 2.38 (95% CI: 1.20\u20134.70) times greater in infants whose mothers had antibody levels <2 \u03bcg/ml for serotypes III and Ia, respectively, compared to infants whose mothers had antibody levels \u22652 \u03bcg/ml [26].",
            "startOffset": 17437,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 18506,
            "parents": [],
            "secId": "sec0025",
            "sentence": "This suggests that prevention of colonization may be another potential and achievable benefit of maternal vaccination as colonization is a pre-requisite for EOD.",
            "startOffset": 18345,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 16432,
            "parents": [],
            "secId": "sec0025",
            "sentence": "The approach taken for a GBS vaccine and the experience gained will have implications for other vaccines also being developed specifically for pregnancy (e.g. RSV).",
            "startOffset": 16268,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 22104,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Infant sera promoted significant opsonophagocytic killing of type III GBS in vitro.",
            "startOffset": 22021,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 10682,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Given the rapid onset and progression of EOD within hours of birth as well as the deficiencies in IAP strategies and absence of a solution for preventing LOD, it is clear that administration of a suitable vaccine in pregnancy could provide a better solution in all settings; it should also be cost effective.",
            "startOffset": 10374,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 10374,
            "parents": [],
            "refoffsets": {
                "bib0240": {
                    "endOffset": 10373,
                    "startOffset": 10366
                },
                "bib0245": {
                    "endOffset": 10373,
                    "startOffset": 10366
                }
            },
            "secId": "sec0005",
            "sentence": "LOD is caused predominantly by serotype III, is acquired perinatally, nosocomially or from community sources, and in up to 50% of cases presents with meningitis, which is associated with significant mortality and long-term morbidity [10,11].",
            "startOffset": 10133,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 22567,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Phase I and II trials of a trivalent GBS vaccine (CRM197-conjugated capsular polysaccharides of GBS serotypes Ia, Ib and III) have been conducted in >600 non-pregnant and >500 pregnant women in four countries.",
            "startOffset": 22358,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 9487,
            "parents": [],
            "refoffsets": {
                "bib0235": {
                    "endOffset": 9486,
                    "startOffset": 9483
                }
            },
            "secId": "sec0005",
            "sentence": "For both strategies IAP is also recommended for women with GBS bacteriuria at any time during their current pregnancy or for women who have had a previous baby with EOD [9].",
            "startOffset": 9314,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 10966,
            "parents": [],
            "secId": "sec0005",
            "sentence": "GBS vaccination alone was predicted to prevent 30\u201354% of infant GBS cases compared to no intervention.",
            "startOffset": 10864,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 20740,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Each GBS conjugate induced high levels of protective antibodies in animals and was shown to be more immunogenic than the unconjugated CPS.",
            "startOffset": 20602,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 13081,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "Multiple studies were undertaken but progress slowed as no vaccine manufacturer appeared willing to progress this candidate to large-scale development, in large part due to perceived issues with the feasibility of maternal immunization.",
            "startOffset": 12845,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 14190,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0290": {
                    "endOffset": 14013,
                    "startOffset": 14009
                },
                "bib0295": {
                    "endOffset": 14189,
                    "startOffset": 14185
                }
            },
            "secId": "sec0015",
            "sentence": "This is exemplified by the World Health Organization's global recommendations on influenza vaccine in pregnant women [20], multiple countries\u2019 recommendations on pertussis vaccine in pregnant women and, in the UK, by the high coverage achieved with a pertussis-containing vaccine in pregnancy [21].",
            "startOffset": 13892,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 10072,
            "parents": [],
            "secId": "sec0005",
            "sentence": "In HIC there are issues with compliance, cost and feasibility (especially of PCR in labour) and more theoretical concerns about the excessive use of antibiotics.",
            "startOffset": 9911,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 18164,
            "parents": [],
            "secId": "sec0025",
            "sentence": "In general, the different methods used and the absence of reference ranges have confounded the interpretation of antibody studies and highlight an urgent need for standardization.",
            "startOffset": 17985,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 13515,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "Randomized clinical trials to evaluate the safety and immunogenicity of vaccination during pregnancy are underway; some have been reported as conference abstracts and some results are available on clinicaltrials.gov (NCT01193920, NCT01446289, NCT02046148).",
            "startOffset": 13259,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 9616,
            "parents": [],
            "refoffsets": {
                "bib0225": {
                    "endOffset": 9615,
                    "startOffset": 9612
                }
            },
            "secId": "sec0005",
            "sentence": "A potential alternative strategy is based on detection of GBS using real time PCR methodology from swabs obtained in labour [7].",
            "startOffset": 9488,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 22740,
            "parents": [],
            "secId": "sec0030",
            "sentence": "These have been designed to assess optimal dose, need for adjuvant, immunogenicity in pregnant women (including HIV-infected), placental transfer and persistence in babies.",
            "startOffset": 22568,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 15550,
            "parents": [],
            "secId": "sec0025",
            "sentence": "The current leading vaccine candidates are capsular polysaccharide-protein conjugate vaccines.",
            "startOffset": 15456,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 7722,
            "parents": [],
            "secId": "sec0005",
            "sentence": "EOD may be rapidly fulminating and cases can therefore be missed before appropriate samples are obtained.",
            "startOffset": 7617,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 23269,
            "parents": [],
            "secId": "sec0030",
            "sentence": "There are a number of obvious advantages with such an approach but until very recently none had entered clinical trials in humans.",
            "startOffset": 23139,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 25343,
            "parents": [],
            "secId": "sec0040",
            "sentence": "PTH is an investigator for clinical trials done on behalf of St George's, University of London, UK, sponsored by vaccine manufacturers including Novartis, Pfizer and GSK.",
            "startOffset": 25173,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 14603,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0020",
            "sentence": "Disease occurs too early in life for neonates or infants to mount an effective immune response following vaccination: the majority of infants with GBS disease present on day 1 of life.",
            "startOffset": 14419,
            "title": "General approaches to vaccine development for this disease for low and middle income country"
        },
        {
            "endOffset": 24573,
            "parents": [],
            "secId": "sec0035",
            "sentence": "This trend is likely to continue until a clear regulatory pathway has been established for vaccine approval in LMICs, and it is established that candidates currently in development are appropriate for LMIC populations.",
            "startOffset": 24355,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 21718,
            "parents": [],
            "secId": "sec0030",
            "sentence": "A total of 20 women in the USA received the vaccine while ten women received a saline control vaccine.",
            "startOffset": 21616,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 9910,
            "parents": [],
            "secId": "sec0005",
            "sentence": "A number of issues arise with this mode of prevention, including its feasibility in LMIC.",
            "startOffset": 9821,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 20093,
            "parents": [],
            "refoffsets": {
                "bib0345": {
                    "endOffset": 20092,
                    "startOffset": 20088
                }
            },
            "secId": "sec0025",
            "sentence": "Finally, an assessment of the impact of vaccine on prematurity, birth asphyxia and stillbirths is also desirable, where possible [31].",
            "startOffset": 19959,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 16166,
            "parents": [],
            "secId": "sec0025",
            "sentence": "A major regulatory issue for this vaccine is that it is being developed specifically for use in pregnant women.",
            "startOffset": 16055,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 21222,
            "parents": [],
            "refoffsets": {
                "bib0355": {
                    "endOffset": 21221,
                    "startOffset": 21217
                }
            },
            "secId": "sec0030",
            "sentence": "In this study adsorption of GBS type III CPS-tetanus toxoid (III-TT) conjugate vaccine to alum did not improve the immune response in healthy adult recipients [33].",
            "startOffset": 21058,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 17872,
            "parents": [],
            "refoffsets": {
                "bib0325": {
                    "endOffset": 17806,
                    "startOffset": 17802
                },
                "bib0330": {
                    "endOffset": 17871,
                    "startOffset": 17867
                }
            },
            "secId": "sec0025",
            "sentence": "Another analysis yielded a threshold of 1 \u03bcg/ml for these STs [27] while other studies have recommended much higher thresholds [28].",
            "startOffset": 17740,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 23138,
            "parents": [],
            "secId": "sec0030",
            "sentence": "A number of groups have identified different surface proteins that are both represented on the surface of all strains and serotypes of the bacterium and able to induce opsonically active antibodies.",
            "startOffset": 22940,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 16761,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Another significant consideration in the development pathway for this vaccine is whether licensure will require large scale randomized placebo controlled trials that demonstrate efficacy against clinical disease, or whether regulatory approval can be based on demonstration of achievement of serological correlates of protection.",
            "startOffset": 16432,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 18709,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Functional assays have also been widely used and are based on opsonophagocytosis, in which vaccine\u2013induced antibodies promote killing of GBS by polymorphonuclear leukocytes in the presence of complement.",
            "startOffset": 18506,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 16859,
            "parents": [],
            "refoffsets": {
                "bib0305": {
                    "endOffset": 16829,
                    "startOffset": 16825
                }
            },
            "secId": "sec0025",
            "sentence": "The latter approach was taken for licensure of meningococcal C [23] and meningococcal B vaccines.",
            "startOffset": 16762,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 19140,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Further prospective studies in diverse settings are still required to confirm/establish protective levels for the common STs (in addition to STIa, III) for EOD as well as for LOD using standardized methods.",
            "startOffset": 18934,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 17154,
            "parents": [],
            "refoffsets": {
                "bib0315": {
                    "endOffset": 17153,
                    "startOffset": 17149
                }
            },
            "secId": "sec0025",
            "sentence": "Baker and colleagues initially characterized the association between serotype-specific CPS antibody levels and invasive GBS disease in newborns in 1976 [25].",
            "startOffset": 16997,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 22890,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The trivalent vaccine appeared to be well tolerated and immunogenic (results presented on clinicaltrials.gov: NCT01193920, NCT01446289, NCT02046148).",
            "startOffset": 22741,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 22188,
            "parents": [],
            "secId": "sec0030",
            "sentence": "All infants were born at term and were healthy through to at least 6 months of age.",
            "startOffset": 22105,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 13720,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "Another manufacturer (MinervaX) has recently commenced phase 1 clinical trials with a protein vaccine (GBS-NN), made from the N-terminal domains of the Rib and AlphaC surface proteins of GBS (NCT02459262).",
            "startOffset": 13515,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 8514,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Maternal carriage of GBS in the gastrointestinal and/or genital tracts is a pre-requisite for EOD, vertical transmission occurring during or just prior to birth.",
            "startOffset": 8353,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 11765,
            "parents": [],
            "secId": "sec0005",
            "sentence": "These are important consequences but are difficult to quantify.",
            "startOffset": 11702,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 24092,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Clinical trials in humans have not yet commenced.",
            "startOffset": 24043,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 8990,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Two major strategies for targeting women to receive IAP are used: risk factor based (RFB) or swab culture-based.",
            "startOffset": 8878,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 17370,
            "parents": [],
            "secId": "sec0025",
            "sentence": "In the majority of subsequent studies lower antibody levels have been found in infants with EOD and LOD, compared with infants who were exposed to mothers colonized with the same ST, but who did not develop disease.",
            "startOffset": 17155,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 24663,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Two cost-effectiveness studies have recently been undertaken in South Africa and the USA.",
            "startOffset": 24574,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 8270,
            "parents": [],
            "secId": "sec0005",
            "sentence": "EOD accounts for approximately 60\u201370% of all neonatal GBS disease.",
            "startOffset": 8204,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 15904,
            "parents": [],
            "refoffsets": {
                "bib0275": {
                    "endOffset": 15869,
                    "startOffset": 15865
                }
            },
            "secId": "sec0025",
            "sentence": "These candidates have so far used conventional carrier proteins (tetanus toxoid, CRM197) [17] (clinicaltrials.gov: NCT01193920).",
            "startOffset": 15776,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 19653,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Should efficacy trials in pregnant women proceed, the main endpoints would include the impact of vaccine against both EOD and LOD, culture proven and ideally, culture negative (clinical sepsis); as well as on maternal disease.",
            "startOffset": 19427,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 7001,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Streptococcus agalactiae (group B streptococcus (GBS)) remains the leading cause of neonatal sepsis and meningitis in many countries and an important cause of disease in pregnant women, immunocompromised adults and the elderly.",
            "startOffset": 6774,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 21316,
            "parents": [],
            "secId": "sec0030",
            "sentence": "A limited number of studies have evaluated the duration of protection following immunization.",
            "startOffset": 21223,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 15016,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0020",
            "sentence": "The only alternative for prevention of EOD (but not LOD) is IAP, but it is generally believed to be too difficult to implement this in LMICs for logistical reasons.",
            "startOffset": 14852,
            "title": "General approaches to vaccine development for this disease for low and middle income country"
        },
        {
            "endOffset": 16055,
            "parents": [],
            "secId": "sec0025",
            "sentence": "The developmental pathway for conjugate vaccines using such proteins is now well established (e.g. Hib/meningococcal/pneumococcal conjugate vaccines).",
            "startOffset": 15905,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 9821,
            "parents": [],
            "secId": "sec0005",
            "sentence": "This method has the obvious advantage of detecting GBS at the most relevant time for IAP, as screening earlier in pregnancy (e.g. 35\u201337 weeks) can result in both false positive and false negative results.",
            "startOffset": 9617,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 23804,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Using a reverse vaccinology approach, investigators from Novartis were able to show that a combination of selected surface-exposed proteins might become the basis of a universal GBS vaccine.",
            "startOffset": 23614,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 16959,
            "parents": [],
            "refoffsets": {
                "bib0310": {
                    "endOffset": 16958,
                    "startOffset": 16954
                }
            },
            "secId": "sec0025",
            "sentence": "Recent guidance lays the groundwork for such an approach for vaccines developed for pregnancy [24].",
            "startOffset": 16860,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 17436,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Different specific levels have been defined in different studies.",
            "startOffset": 17371,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 7400,
            "parents": [],
            "refoffsets": {
                "bib0195": {
                    "endOffset": 7399,
                    "startOffset": 7396
                }
            },
            "secId": "sec0005",
            "sentence": "Intrapartum antibiotic (IAP) strategies have reduced the incidence of early-onset neonatal GBS (EOD, defined as disease occurring <7 days of age) where applied, but have had no impact on late onset GBS infection (LOD, 7\u201390 days of age) and only a limited impact on disease in pregnant women [1].",
            "startOffset": 7105,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 11701,
            "parents": [],
            "refoffsets": {
                "bib0255": {
                    "endOffset": 11700,
                    "startOffset": 11696
                }
            },
            "secId": "sec0005",
            "sentence": "There is also evidence that GBS may contribute to prematurity, birth asphyxia and stillbirths; for example, a recent systematic review estimated it might account for up to 12% of stillbirths [13].",
            "startOffset": 11505,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 13891,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "Additionally and most significantly, the attitude of healthcare workers, the general public, regulators and policy makers towards vaccination during pregnancy has changed.",
            "startOffset": 13720,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 18344,
            "parents": [],
            "refoffsets": {
                "bib0340": {
                    "endOffset": 18343,
                    "startOffset": 18339
                }
            },
            "secId": "sec0025",
            "sentence": "In a longitudinal study of natural antibody and colonization, thresholds of \u22653 \u03bcg/ml for prevention of colonization with GBS ST1a and III and of 1 \u03bcg/ml for STV were proposed [30].",
            "startOffset": 18164,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 17984,
            "parents": [],
            "refoffsets": {
                "bib0335": {
                    "endOffset": 17983,
                    "startOffset": 17979
                }
            },
            "secId": "sec0025",
            "sentence": "There has been considerable controversy regarding the appropriateness of the different ELISA methods used [29].",
            "startOffset": 17873,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 11255,
            "parents": [],
            "secId": "sec0005",
            "sentence": "RFB-IAP alone, compared to doing nothing, prevented 10% of infant GBS cases at a cost of $240/DALY.",
            "startOffset": 11156,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 11328,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Vaccine plus RFB-IAP prevented 48% of cases at a cost of $664\u20132128/DALY.",
            "startOffset": 11256,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 14418,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0020",
            "sentence": "The leading indication for GBS vaccines is the prevention of neonatal GBS infections (up to 2\u20133 months of age), including meningitis.",
            "startOffset": 14285,
            "title": "General approaches to vaccine development for this disease for low and middle income country"
        },
        {
            "endOffset": 11155,
            "parents": [],
            "secId": "sec0005",
            "sentence": "For vaccine prices between $10 and $30, and mid-range efficacy, its cost ranged from $676 to $2390 per disability-adjusted life-year (DALY) averted ($US 2010), compared to no intervention.",
            "startOffset": 10967,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 24945,
            "parents": [],
            "refoffsets": {
                "bib0250": {
                    "endOffset": 24944,
                    "startOffset": 24940
                }
            },
            "secId": "sec0035",
            "sentence": "In the South African study, maternal GBS vaccination was found to be very cost effective per WHO guidelines at prices up to $30/dose [12].",
            "startOffset": 24807,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 21057,
            "parents": [],
            "secId": "sec0030",
            "sentence": "All published studies have used conjugate vaccines without an adjuvant, with one exception.",
            "startOffset": 20966,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 21535,
            "parents": [],
            "refoffsets": {
                "bib0360": {
                    "endOffset": 21534,
                    "startOffset": 21530
                }
            },
            "secId": "sec0030",
            "sentence": "In one study the duration of functional activity following a GBS conjugate vaccine was evaluated among healthy adult responders and showed substantial functional activity at 18 months to 2 years post-immunization [34].",
            "startOffset": 21317,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 8107,
            "parents": [],
            "secId": "sec0005",
            "sentence": "A recent meta-analysis emphasized this and reported an overall estimate of GBS incidence of 0.53 per 1000 live births and a mean case fatality ratio of 9.6% (95% CI 7.5\u201311.8).",
            "startOffset": 7932,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 9313,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The former is based on the presence of any of the following intrapartum risk factors: delivery at <37 weeks\u2019 gestation, intrapartum fever, or rupture of membranes for \u226518 h; while the latter is based on a positive vaginal-rectal swab, typically obtained at 35\u201337 weeks gestation and cultured for GBS using selective media.",
            "startOffset": 8991,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 20601,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Experimental conjugates were subsequently constructed with CPS of GBS serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII.",
            "startOffset": 20483,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 20482,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Conjugate vaccines were also shown to have efficacy in animal models.",
            "startOffset": 20413,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 12075,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0260": {
                    "endOffset": 12074,
                    "startOffset": 12070
                }
            },
            "secId": "sec0015",
            "sentence": "In the 1930s, Rebecca Lancefield demonstrated that protection against GBS infection in mice could be achieved using capsular polysaccharide (CPS)-specific rabbit sera [14].",
            "startOffset": 11903,
            "title": "EITHER vaccines currently available and their limitations OR Biological feasibility for vaccine development"
        },
        {
            "endOffset": 15420,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0250": {
                    "endOffset": 15419,
                    "startOffset": 15415
                }
            },
            "secId": "sec0020",
            "sentence": "The South African cost-effectiveness data suggested that GBS vaccination might prevent 30\u201354% of infant GBS cases while RFB-IAP might prevent only 10% of infant GBS cases [12].",
            "startOffset": 15244,
            "title": "General approaches to vaccine development for this disease for low and middle income country"
        },
        {
            "endOffset": 20350,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Vaccination was generally well tolerated.",
            "startOffset": 20309,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 22939,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Other vaccine targets include conserved proteins.",
            "startOffset": 22890,
            "title": "Status of vaccine R&D activities"
        }
    ],
    "docId": "S0264410X16002905",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "pheath@sgul.ac.uk",
                "first": "Paul T.",
                "initial": "P.T.",
                "last": "Heath"
            }
        ],
        "doi": "10.1016/j.vaccine.2015.12.072",
        "firstpage": "2876",
        "issn": "0264410X",
        "keywords": [
            "Conjugate",
            "Group B streptococcus",
            "Pregnancy",
            "Streptococcus agalactiae",
            "Vaccine"
        ],
        "lastpage": "2879",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Status of vaccine research and development of vaccines for GBS"
    }
}